Yahoo Finance

ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

Clearside Biomedical Details Phase 3 Program for CLS-AX in Wet AMD Following Positive FDA Meeting

Receipt of formal meeting minutes from the FDA confirming key elements for two proposed Phase 3 pivotal trials indicates regulatory progress and alignment with the FDA. Positive outcome of the ...
Nasdaq

Clearside Biomedical Highlights CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial at Upcoming Conferences

Clearside Biomedical announces upcoming presentations on CLS-AX sub-group analyses from the ODYSSEY Wet AMD trial at various conferences. Clearside Biomedical, Inc. announced upcoming presentations ...
Your Story

Aligning business processes with dynamics AX – challenges?

This is a user generated content for MyStory, a YourStory initiative to enable its community to contribute and have their voices heard. The views and writings here ...
Business Insider

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with Duration of ...